Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Florida
With
National Institute of General Medical Sciences (NIGMS)
This research study will be a prospective, open-label 18-week clinical study of nebivolol in patients with PH associated with HFpEF. Patients will be identified in clinic based on echocardiogram (TTE) and right heart catheterization (RHC) results (both part of standard clinical care) indicating PH and HFpEF.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults (≥ 18 years of age) with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure ≥ 25 mmHg and pulmonary capillary wedge pressure ≥ 15 mmHg)
New York Heart Association class II-IV symptoms
Left ventricular ejection fraction (LVEF) ≥ 45%
You may not be if
Other causes of heart failure other than diastolic dysfunction, such as restrictive cardiomyopathy or infiltrative cardiomyopathy
Women who are pregnant or nursing
Liver cirrhosis,
Primary valvular disease
Acute coronary syndrome
Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis
Severe bradycardia or greater than 1st degree heart block
Decompensated heart failure
Current use of a third generation beta-blocker (nebivolol, carvedilol, or labetalol) or high dose of any beta-blockers (greater than 100 mg daily of metoprolol, or equivalent)
